Retatrutide
Also known as: LY3437943, triple hormone receptor agonist, GIP/GLP-1/glucagon triple agonist
Synthetic triple receptor agonist peptide (GIP/GLP-1/glucagon receptor agonist)
What it is
Retatrutide is an investigational weight-loss drug in Phase 3 clinical trials, designed for obesity and type 2 diabetes. It activates three hormone pathways simultaneously — producing some of the largest weight reductions seen in clinical trials to date. Not FDA-approved; under active Phase 3 development.
The scientific side
Retatrutide (LY3437943) is a novel synthetic peptide that acts as a triple agonist simultaneously activating three hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR) (PMIDs: 41090431, 37366315, 37385280). Through GLP-1R agonism, retatrutide increases insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite and food intake. GIP receptor agonism provides complementary incretin effects that enhance glycemic control and weight loss. Glucagon receptor agonism promotes energy expenditure and fatty acid oxidation, contributing to additional weight and liver fat reduction (PMIDs: 42858523, 40563436). The molecule increases adenylyl cyclase activity and elevates cyclic AMP (cAMP) levels through all three cognate receptors. In isolated human atrial preparations, retatrutide increased force of contraction in a concentration-dependent manner via cAMP-mediated signaling through GLP-1R, GIPR, and GCGR. Mechanistically, retatrutide also reduces circulating ANGPTL3/8 complex concentrations — an effect attributed to GCGR agonism — which may contribute to reductions in triglycerides and LDL-C. Pharmacokinetic data from Phase 1/2 trials indicate dose-proportional pharmacokinetics and a mean half-life of approximately 6 days, supporting once-weekly dosing.
Class: Synthetic triple receptor agonist peptide (GIP/GLP-1/glucagon receptor agonist)
Administration & storage
- Administration
- Subcutaneous injectiononce weekly (PMID: 37366315)Subcutaneous injectiononce weekly (PMID: 37385280)Subcutaneous injectiononce weekly (PMID: 38858523)Subcutaneous injectiononce weekly (PMID: 42250575)Subcutaneous injectiononce weekly (PMID: 41090431)Subcutaneous injectiononce weekly (PMID: 41160422)
- Storage
- Storage conditions for retatrutide are not described in the reviewed abstracts.
- Cautions
- Retatrutide is an investigational compound; as of the reviewed literature it is not FDA-approved for any indication. Use outside of supervised clinical trials is unregulated and carries unknown risks.,Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) were the most commonly reported adverse effects across Phase 1, 2, and 3 trials, were dose-related, and were partially mitigated by lower starting doses and slower dose escalation (PMIDs: 37366315, 37385280, 42250575).,Dose-dependent increases in heart rate were observed in the Phase 2 obesity trial, peaking at Week 24 and declining thereafter.,No severe hypoglycemia was reported in the Phase 2 trials in T2D or the Phase 3 T2D trial; however, two deaths occurred in the Phase 3 trial (both in the 4 mg group, assessed as unrelated to study drug).,Unregulated injectable peptides including retatrutide purchased outside of clinical or prescriptive channels may carry risks of product contamination, manufacturing impurities, and inaccurate dosing.,Sterile technique is essential for any injectable preparation to prevent contamination.
Legal & regulatory status
Not approved as of the reviewed literature period; described as investigational/under clinical development (Phase 2 and Phase 3 trials ongoing). One abstract characterizes it as an 'investigational triple-agonist'…
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Obesity / weight management (adults with overweight or obesity without diabetes) Mixed
- Phase 2 RCT (n=338, 48 weeks, subcutaneous once-weekly). Least-squares mean percentage change in body weight at 48 weeks: -8.7% (1 mg), -17.1% (combined 4 mg), -22.8% (combined 8 mg), -24.2% (12 mg) vs. -2.1% placebo. At 48 weeks, 100% of 8 mg and 12 mg participants achieved ≥5% weight loss; 83% (12 mg) achieved ≥15%. PMID 37366315 Jastreboff AM et al. N Engl J Med. 2023
- Systematic review: Retatrutide 12 mg once weekly produced weight loss of up to 22.1% (95% CI 19.3%–24.9%) after 48 weeks compared with placebo, exceeding tirzepatide and semaglutide at corresponding follow-up. PMID 39761578 Moiz A et al. Ann Intern Med. 2025
- Network meta-analysis: retatrutide 12 mg (-22.10% body weight, -17.00 cm waist circumference) and 8 mg (-20.70%, -15.90 cm) were the two most efficacious treatments vs. placebo among GLP-1 receptor agonists and polyagonists assessed. PMID 39305981 Xie Z et al. Metabolism. 2024
- Bayesian NMA: retatrutide achieved equivalent mean weight loss to dual agonists (-11.0 kg), surpassing GLP-1RAs (-9.0 kg), and excelled at achieving ≥15% weight loss (OR 54.6). Retatrutide had the highest AE risk. PMID 40685589 Sinha B, Ghosal S. Obesity (Silver Spring). 2025
- Systematic review and meta-analysis of 4 RCTs: 12 mg dose showed the most significant reductions in body weight, BMI, and waist circumference, and the highest proportions achieving ≥5%, ≥10%, ≥15%, and ≥20% weight loss. Safety profile comparable to control. PMID 39817343 Tewari J et al. Expert Rev Clin Pharmacol. 2025
- Type 2 diabetes mellitus — glycemic control and weight reduction Mixed
- Phase 2 RCT (n=281, 36 weeks, USA). In people with T2D, retatrutide reduced HbA1c by up to -2.02% (12 mg) vs. -0.01% placebo at 24 weeks. Bodyweight decreased dose-dependently up to -16.94% (12 mg) vs. -3.00% placebo at 36 weeks. Mild-to-moderate GI AEs most common. No severe hypoglycemia or deaths. PMID 37385280 Rosenstock J et al. Lancet. 2023
- Phase 3 RCT (n=537, 40 weeks, USA/Mexico/India). Retatrutide as monotherapy for T2D inadequately controlled by diet/exercise: mean HbA1c change -1.69% (4 mg), -1.86% (9 mg), -1.94% (12 mg) vs. -0.81% placebo (all p<0.0001). Mean bodyweight change: -11.5% (4 mg), -13.9% (9 mg), -15.3% (12 mg) vs. -2.6% placebo. No sever PMID 42250575 Bajaj HS et al. Lancet. 2026
- Review: HbA1c decreased by up to 2.16% and fasting glucose by up to 69.1 mg/dL in subjects with T2DM. Weight loss up to 16.94% in T2DM subjects. GI adverse events (nausea, vomiting, constipation, diarrhea) most frequent at highest doses, partly attributable to rapid dose escalation. PMID 41785010 Panou T et al. Expert Rev Clin Pharmacol. 2026
- Metabolic dysfunction-associated steatotic liver disease (MASLD) / liver fat reduction Mixed
- Phase 2a RCT substudy (n=98, 48 weeks subcutaneous once-weekly). Mean relative change from baseline in liver fat at 24 weeks: -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg) vs. +0.3% placebo (all p<0.001 vs. placebo). Normal liver fat (<5%) achieved by 86% (12 mg) vs. 0% placebo at 24 weeks. PMID 38858523 Sanyal AJ et al. Nat Med. 2024
- Review: retatrutide reduced hepatic fat on MRI-PDFF placebo-subtracted by 81% after 48–72 weeks, the largest reduction reported among semaglutide, tirzepatide, and retatrutide. PMID 40554267 Rodriguez N, Hartmann P. Pharmacol Rev. 2025
- Systematic review and meta-analysis: among GLP-1RAs studied, retatrutide displayed the most obvious treatment effects on liver fat content reduction. PMID 40489581 Wang Y et al. J Clin Endocrinol Metab. 2025
- Body composition — fat mass reduction in type 2 diabetes Human RCT
- Phase 2 body composition substudy (n=189 enrolled, 103 completed, DXA-measured). Percent reduction in total fat mass: 26.1% (8 mg pooled), 23.2% (12 mg), 15.2% (4 mg pooled), 4.9% (0.5 mg) vs. 4.5% placebo and 2.6% dulaglutide. Proportion of lean mass loss to total weight loss was similar to other obesity treatments. PMID 40609566 Coskun T et al. Lancet Diabetes Endocrinol. 2025
- Blood pressure and lipid profile improvement Human RCT
- Systematic review and meta-analysis of RCTs: retatrutide significantly decreased systolic BP (WMD -6.79 mmHg, 95% CI -8.36 to -5.23, p<0.0001), diastolic BP (WMD -2.46 mmHg, p<0.0001), total cholesterol (WMD -21.88 mg/dL), LDL-C (WMD -13.10 mg/dL), and triglycerides (WMD -40.90 mg/dL). No significant effect on HDL-C. PMID 42371360 Simental-Mendía LE et al. High Blood Press Cardiovasc Prev. 2026
- Post-hoc analysis of two phase 2 RCTs: ANGPTL3/8 reductions observed with 8 mg and 12 mg retatrutide in T2D participants and with 1, 4, 8, and 12 mg in participants with obesity/overweight without diabetes. ANGPTL3/8 decreases paralleled TG and LDL-C reductions. In vitro: glucagon and retatrutide decreased ANGPTL3/8 se PMID 40726454 Wen Y et al. Diabetes Obes Metab. 2025
- Appetite modulation and eating behavior modification Human RCT
- Phase 2 pre-specified exploratory analysis (n=275, T2D). Retatrutide ≥4 mg vs. placebo: greater reductions in overall appetite, hunger, and prospective food consumption at Week 24 (all p<0.05). At 8 mg and 12 mg: greater improvements in Perceived Hunger and Disinhibition vs. placebo at Weeks 24 and 36. Dietary Restrain PMID 40916752 Kanu C et al. Diabetes Obes Metab. 2025
- Obstructive sleep apnea (OSA) — Phase 3 investigation Human RCT
- TRIUMPH Phase 3 program design: OSA protocols nested within TRIUMPH-1 and TRIUMPH-2 weight management basket trials (>5800 total participants). Primary OSA endpoint is change in Apnea-Hypopnea Index. Results not yet reported in this design publication. PMID 41090431 Giblin K et al. Diabetes Obes Metab. 2026
- Knee osteoarthritis — Phase 3 investigation Human RCT
- TRIUMPH Phase 3 program design: OA protocols nested in TRIUMPH-1/-2 and a stand-alone OA trial (TRIUMPH-4, >5800 total participants). Primary OA endpoint: change in WOMAC pain subscale score. Results not yet reported. PMID 41090431 Giblin K et al. Diabetes Obes Metab. 2026
- Chronic kidney disease — Phase 2 investigation Human observational
- TRANSCEND-CKD Phase 2b mechanistic study (n=146 randomized, eGFR 25–75 mL/min/1.73 m², with/without T2D). Participants randomized 1:1 to once-weekly retatrutide maximum tolerated dose up to 12 mg or placebo. Primary endpoint: change in measured GFR by iohexol clearance at Week 24. Results pending. PMID 41160422 Heerspink HJL et al. Nephrol Dial Transplant. 2026
- Triple-negative breast cancer (TNBC) in obesity — preclinical investigation Animal studies only
- Preclinical study: retatrutide inhibited the hexosamine biosynthetic pathway (HBP) and YAP O-GlcNAcylation, leading to increased YAP degradation and decreased tumor size in obese mice bearing TNBC tumors. Enhanced chemotherapy efficacy observed, particularly in obese mice. Mechanism involved EIF3H-mediated deubiquityla PMID 39868848 Cui X et al. Adv Sci. 2025
- Cardiac inotropic effects — in vitro/ex vivo human tissue In vitro only
- Ex vivo human right atrial preparations (open heart surgery patients): retatrutide (10–100 nM, cumulative) elevated force of contraction in a concentration- and time-dependent manner via cAMP through GLP-1R, GIPR, and GCGR. Effects diminished by respective receptor antagonists, ryanodine, carbachol, and adenosine recep PMID 40613938 Neumann J et al. Naunyn Schmiedebergs Arch Pharmacol. 2026
Safety signals
- Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) — most common AEs across trials; dose-related, mostly mild-to-moderate; partially mitigated by lower starting doses and slower escalation PMID 37366315
- Gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) reported in 35% of retatrutide-treated participants (vs. 13% placebo) in Phase 2 T2D trial; higher frequency with faster escalation (50% at 8 mg fast escalation vs. 13% placebo) PMID 37385280
- Dose-dependent increases in heart rate peaking at 24 weeks and declining thereafter in Phase 2 obesity trial PMID 37366315
- Two deaths in Phase 3 T2D trial (both in the retatrutide 4 mg group), assessed by investigators as unrelated to study drug; discontinuations due to AEs 2–5% with retatrutide vs. 0% with placebo PMID 42250575
- Higher AE risk with retatrutide compared to dual agonists and GLP-1RAs in Bayesian network meta-analysis (highest AE risk among agents compared) PMID 40685589
- Serious adverse events occurred in 3–9% of participants across treatment groups in the body composition substudy (Phase 2, T2D); no deaths reported in this substudy PMID 40609566
- Increased frequency of mild-to-moderate GI adverse events at highest doses, likely due to rapid dose escalation and higher starting dose, noted in review PMID 41785010
- GLP-1 receptor agonist class signal: slightly increased risk of pancreatitis in meta-analysis of GLP-1 RA RCTs (including retatrutide); pancreatic cancer risk not significantly elevated overall PMID 40988099
- Positive inotropic effects on isolated human atrial preparations at 10–100 nM; clinical cardiovascular significance of this ex vivo finding is not established in the reviewed abstracts PMID 40613938
- Described as lacking established human safety profile when used outside clinical supervision; risks of contamination, manufacturing impurities, inaccurate dosing, and supraphysiological hormonal signaling noted for unregulated use PMID 42757290
Contraindications
- No absolute contraindications are explicitly stated in the reviewed abstracts. Phase 2 T2D trial excluded participants outside the age range 18–75 years or outside HbA1c 7.0–10.5% and BMI 25–50 kg/m²; these represent study eligibility criteria, not formally stated contraindications. PMID 37385280
- Phase 3 T2D trial enrolled adults ≥18 years with BMI ≥23 kg/m² and HbA1c 7.0–9.5%; populations outside these parameters were not studied in this trial. PMID 42250575
- GLP-1 receptor agonist class: more severe side effects include pancreatitis, allergic reactions, renal function disorders, and possibly increased risk of thyroid cancer, noted as class concerns for GLP-1 RAs including retatrutide. PMID 40042613
Protocol
2 mg subcutaneous injection, once weekly. Cycle: 4 weeks (starting ramp phase).
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Subcutaneous injection, once weekly | 1 mg, 4 mg (initial dose 2 mg or 4 mg), 8 mg (initial dose 2 mg or 4 mg), or 12 mg (initial dose 2 mg) once weekly subcutaneous | 48 weeks | human | Research PMID 37366315 |
| Subcutaneous injection, once weekly | 0.5 mg, 4 mg (starting dose 2 mg), 4 mg (no escalation), 8 mg (starting dose 2 mg), 8 mg (starting dose 4 mg), or 12 mg (starting dose 2 mg) once weekly subcutaneous; active comparator: dulaglutide 1.5 mg once weekly | 36 weeks | human | Research PMID 37385280 |
| Subcutaneous injection, once weekly | 1 mg, 4 mg, 8 mg, or 12 mg once weekly subcutaneous | 48 weeks | human | Research PMID 38858523 |
| Subcutaneous injection, once weekly | 0.5 mg, 4 mg (2 mg initial dose), 4 mg (4 mg initial dose), 8 mg (2 mg initial dose), 8 mg (4 mg initial dose), or 12 mg once weekly subcutaneous | 36 weeks | human | Research PMID 40609566 |
| Subcutaneous injection, once weekly | 0.5 mg, 4 mg, 8 mg, or 12 mg once weekly subcutaneous | 36 weeks | human | Research PMID 40916752 |
| Subcutaneous injection, once weekly | Maximum tolerated dose up to 12 mg once weekly subcutaneous | 24 weeks (primary endpoint); ongoing | human | Research PMID 41160422 |
| Subcutaneous injection, once weekly | 4 mg, 9 mg, or 12 mg once weekly subcutaneous | 40 weeks | human | Research PMID 42250575 |
| Subcutaneous injection, once weekly | Weekly subcutaneous retatrutide (specific dose not stated in design abstract); compared to placebo | Phase 3 multicenter trials (duration not specified in abstract) | human | Research PMID 41090431 |
| In vitro/ex vivo (isolated human atrial preparations) | 10 nM to 100 nM (cumulative concentrations applied ex vivo) | Acute ex vivo experiment | in_vitro | Research PMID 40613938 |
| subcutaneous injection | 2 mg | once weekly · 4 weeks (starting ramp phase) | biohackers and self-experimenters pursuing aggressive fat loss / body recomposition | [Community] |
| subcutaneous injection | 4 mg | once weekly · 4 weeks | biohackers and self-experimenters pursuing fat loss after tolerating 2 mg | [Community] |
| subcutaneous injection | 6 mg | once weekly · 4-8 weeks | biohackers pursuing aggressive fat loss; individuals with obesity or high starting body weight | [Community] |
| subcutaneous injection | 8 mg | once weekly · 8-12 weeks | experienced biohackers tolerating lower doses; individuals with significant weight loss goals | [Community] |
| subcutaneous injection | 12 mg | once weekly · 8-12 weeks | aggressive biohackers; typically heavier individuals or those specifically chasing maximum fat loss outcomes | [Community] |
| subcutaneous injection | 2 mg → 4 mg → 6 mg → 8 mg | once weekly per step · 4 weeks per step (16 weeks total to reach 8 mg) | biohackers and self-experimenters new to GLP-1/triple agonist class peptides | [Community] |
| subcutaneous injection | 4 mg | once weekly · ongoing / indefinite maintenance | biohackers who reached target weight or body composition and are transitioning to maintenance | [Community] |
| subcutaneous injection | 2 mg | once weekly · ongoing | lean biohackers using Retatrutide for metabolic health or longevity rather than aggressive fat loss | [Community] |
Blends containing this peptide
All studies (25)
- PMID 40609566 Human RCT
Body composition — fat mass reduction in type 2 diabetes - PMID 40726454 Human RCT
Blood pressure and lipid profile improvement - PMID 40916752 Human RCT
Appetite modulation and eating behavior modification - PMID 41090431 Human RCT
Obstructive sleep apnea (OSA) — Phase 3 investigation - PMID 42371360 Human RCT
Blood pressure and lipid profile improvement - PMID 41160422 Human observational
Chronic kidney disease — Phase 2 investigation - PMID 37366315 Mixed
Obesity / weight management (adults with overweight or obesity without diabetes) - PMID 37385280 Mixed
Type 2 diabetes mellitus — glycemic control and weight reduction - PMID 38858523 Mixed
Metabolic dysfunction-associated steatotic liver disease (MASLD) / liver fat reduction - PMID 39305981 Mixed
Obesity / weight management (adults with overweight or obesity without diabetes) - PMID 39761578 Mixed
Obesity / weight management (adults with overweight or obesity without diabetes) - PMID 39817343 Mixed
Obesity / weight management (adults with overweight or obesity without diabetes) - PMID 40489581 Mixed
Metabolic dysfunction-associated steatotic liver disease (MASLD) / liver fat reduction - PMID 40554267 Mixed
Metabolic dysfunction-associated steatotic liver disease (MASLD) / liver fat reduction - PMID 40685589 Mixed
Obesity / weight management (adults with overweight or obesity without diabetes) - PMID 41785010 Mixed
Type 2 diabetes mellitus — glycemic control and weight reduction - PMID 42250575 Mixed
Type 2 diabetes mellitus — glycemic control and weight reduction - PMID 18560436
- PMID 39724554
- PMID 39868848 Animal studies only
Triple-negative breast cancer (TNBC) in obesity — preclinical investigation - PMID 40042613
GLP-1 receptor agonist class: more severe side effects include pancreatitis, allergic reactions, renal function disorders, and possibly increased risk of thyroi - PMID 40613938 In vitro only
Cardiac inotropic effects — in vitro/ex vivo human tissue - PMID 40988099
GLP-1 receptor agonist class signal: slightly increased risk of pancreatitis in meta-analysis of GLP-1 RA RCTs (including retatrutide); pancreatic cancer risk n - PMID 41545327
- PMID 42757290
Described as lacking established human safety profile when used outside clinical supervision; risks of contamination, manufacturing impurities, inaccurate dosin